#South Korea #Seoul #Clinical Trials #Sky Labs #CART BP pro

Sky Labs Introduces 'CART BP pro'

On July 2, 2026, Sky Labs, led by CEO Jack Byunghwan Lee, made headlines at the 9th Digital Biomarkers in Clinical Trials Summit held in Basel, Switzerland. They showcased their cutting-edge data platform, emphasizing the promising role of their ring-type cuffless blood pressure monitor, 'CART BP pro', in clinical trials and Real-World Evidence (RWE) data collection.

The summit gathered around 350 attendees, including key players from multinational pharmaceutical firms, clinical trial experts, and digital healthcare innovators. These delegates exchanged insights on leveraging wearable devices and digital health technologies to enhance clinical trial methodologies. The event took place in Basel, noted for housing Roche's headquarters, which lent added significance to the discussions.

Through their participation in this prominent gathering, Sky Labs aims to establish itself as a pivotal partner for global pharmaceutical companies by providing reliable, high-quality vital signs data, which is collected with patient consent. In South Korea, the effectiveness of this platform is already in the spotlight, having been validated in state-led research and utilized in a large-scale cohort study by the National Institutes of Health (NIH) under the Korea Disease Control and Prevention Agency (KDCA).

Addressing Industry Issues

During the summit, Sky Labs shared compelling real-world data that showcased the potential of CART BP pro as a viable clinical data platform. The company highlighted significant shortcomings associated with conventional cuff-type 24-hour ambulatory blood pressure monitoring (ABPM) devices, which are commonplace in clinical trials. These devices often lead to sleep disturbances and discomfort for participants during nighttime measurements, consequently increasing dropout rates, inflating costs, and extending clinical timelines. A pivotal study noted that over 70% of users experienced sleep disruptions attributable to these cuff devices, which ultimately hinder data collection efforts.

In stark contrast, CART BP pro is a user-friendly ring-type monitor designed to be worn on the finger. It can gather vital blood pressure data seamlessly throughout daily activities and even during sleep, eliminating the discomfort and restriction caused by traditional arm cuffs. This design lessens the measurement burden for subjects, facilitating consistent, reliable collection of vital signs data such as blood pressure and heart rate over prolonged periods.

Moreover, CART BP pro’s application extends beyond drug trials; it is also beneficial in assessing therapeutic responses to existing medications. By continually monitoring blood pressure changes linked to medication dosages and lifestyle factors, the device provides essential RWE data that are critical for evaluating drug efficacy, safety, and overall patient prognosis.

Currently, CART BP pro enjoys coverage under South Korea's national health insurance system and has established clinical credibility as a certified cuffless blood pressure monitor, in accordance with the latest Korean Guidelines for the Management of Hypertension.

Future Plans

In the words of CEO Jack Byunghwan Lee, "Our technology, validated by the Korean Society of Hypertension (KSH) guidelines and recognized for health insurance coverage, demonstrates its potential to be a high-quality data platform for clinical trials." The company is focused on expanding its usage scenarios in clinical trials through strategic collaborations with global pharmaceutical firms.

Sky Labs, founded in 2015, has dedicated itself to enhancing healthcare through pioneering technologies. Following the successful medical device approval for CART BP pro in 2023, the company has continued to broaden its horizons, including the recent launch of a consumer-grade ring-type blood pressure monitor, CART BP, in 2025. With CART BP pro, Sky Labs continues to push the boundaries of what is achievable in the realm of clinical trials and patient monitoring, revolutionizing the way we consider blood pressure measurement.